{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:44:26Z","timestamp":1774982666315,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Genom. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) is one of the most lethal malignancies. The extreme heterogeneity in survival rate is driving the need for new prognostic biomarkers. Human endogenous retroviruses (hERVs) have been suggested to influence tumor progression, oncogenesis and elicit an immune response. We examined multiple next-generation sequencing (NGS)-derived biomarkers in 114 CRC patients with paired whole-exome and whole-transcriptome sequencing (WES and WTS, respectively). First, we demonstrate that the median expression of hERVs can serve as a potential biomarker for prognosis, relapse, and resistance to chemotherapy in stage II and III CRC. We show that hERV expression and CD8+ tumor-infiltrating T-lymphocytes (TILs) synergistically stratify overall and relapse-free survival (OS and RFS): the median OS of the CD8-\/hERV+ subgroup was 29.8 months compared with 37.5 months for other subgroups (HR\u2009=\u20094.4, log-rank <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Combing NGS-based biomarkers (hERV\/CD8 status) with clinicopathological factors provided a better prediction of patient survival compared to clinicopathological factors alone. Moreover, we explored the association between genomic and transcriptomic features of tumors with high hERV expression and establish this subtype as distinct from previously described consensus molecular subtypes of CRC. Overall, our results underscore a previously unknown role for hERVs in leading to a more aggressive subtype of CRC.<\/jats:p>","DOI":"10.1038\/s41525-021-00177-w","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:31:41Z","timestamp":1613572301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["HERVs establish a distinct molecular subtype in stage II\/III colorectal cancer with poor outcome"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8981-0047","authenticated-orcid":false,"given":"Mahdi","family":"Golkaram","sequence":"first","affiliation":[]},{"given":"Michael L.","family":"Salmans","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3497-3196","authenticated-orcid":false,"given":"Shannon","family":"Kaplan","sequence":"additional","affiliation":[]},{"given":"Raakhee","family":"Vijayaraghavan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-9380","authenticated-orcid":false,"given":"Marta","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Nafeesa","family":"Khan","sequence":"additional","affiliation":[]},{"given":"Cassandra","family":"Garbutt","sequence":"additional","affiliation":[]},{"given":"Aaron","family":"Wise","sequence":"additional","affiliation":[]},{"given":"Joyee","family":"Yao","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Casimiro","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Abreu","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"Ana L\u00facia","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Cec\u00edlia","family":"Alvim","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9","family":"Mansinho","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Filipe","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Marques da Costa","sequence":"additional","affiliation":[]},{"given":"Afonso","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Borralho","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Aldeia","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Malaquias","sequence":"additional","affiliation":[]},{"given":"Jim","family":"Godsey","sequence":"additional","affiliation":[]},{"given":"Alex","family":"So","sequence":"additional","affiliation":[]},{"given":"Traci","family":"Pawlowski","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Shile","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"177_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jim-2016-000229","volume":"65","author":"A Bhandari","year":"2017","unstructured":"Bhandari, A., Woodhouse, M. & Gupta, S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J. Investig. Med. 65, 311\u2013315 (2017).","journal-title":"J. Investig. Med."},{"key":"177_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.12998\/wjcc.v6.i15.869","volume":"6","author":"M Vacante","year":"2018","unstructured":"Vacante, M., Borz\u00ec, A. M., Basile, F. & Biondi, A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J. Clin. Cases 6, 869\u2013881 (2018).","journal-title":"World J. Clin. Cases"},{"key":"177_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdz287","volume":"30","author":"R Dienstmann","year":"2019","unstructured":"Dienstmann, R. et al. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II\/III colorectal cancer. Ann. Oncol. 30, 1622\u20131629 (2019).","journal-title":"Ann. Oncol."},{"key":"177_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrclinonc.2011.15","volume":"8","author":"S Van Schaeybroeck","year":"2011","unstructured":"Van Schaeybroeck, S., Allen, W. L., Turkington, R. C. & Johnston, P. G. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat. Rev. Clin. Oncol. 8, 222\u2013232 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"177_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0776-6","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 9, 739 (2018).","journal-title":"Cell Death Dis."},{"key":"177_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Disco. 6, 202\u2013216 (2016).","journal-title":"Cancer Disco."},{"key":"177_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3878","volume":"15","author":"HT Lynch","year":"2015","unstructured":"Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D. & Hitchins, M. P. Milestones of Lynch syndrome: 1895\u20132015. Nat. Rev. Cancer 15, 181\u2013194 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"177_CR8","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"177_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery, S., Keegan, P. & Pazdur, R. First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication. N. Engl. J. Med. 377, 1409\u20131412 (2017).","journal-title":"N. Engl. J. Med."},{"key":"177_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"177_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79\u201392 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"177_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/mp.56.1.11","volume":"56","author":"PN Nelson","year":"2003","unstructured":"Nelson, P. N. et al. Demystified\u2026 Human endogenous retroviruses. J. Clin. Pathol. - Mol. Pathol. 56, 11\u201318 (2003).","journal-title":"J. Clin. Pathol. - Mol. Pathol."},{"key":"177_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/v9060130","volume":"9","author":"T Hurst","year":"2017","unstructured":"Hurst, T. & Magiorkinis, G. Epigenetic control of human endogenous retrovirus expression: focus on regulation of long-terminal repeats (LTRs). Viruses 9, 130 (2017).","journal-title":"Viruses"},{"key":"177_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1128\/MCB.01293-14","volume":"35","author":"S Schlesinger","year":"2015","unstructured":"Schlesinger, S. & Goff, S. P. Retroviral transcriptional regulation and embryonic stem cells: war and peace. Mol. Cell. Biol. 35, 770\u2013777 (2015).","journal-title":"Mol. Cell. Biol."},{"key":"177_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030010","volume":"3","author":"YN Lee","year":"2007","unstructured":"Lee, Y. N. & Bieniasz, P. D. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3, e10 (2007).","journal-title":"PLoS Pathog."},{"key":"177_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-6","volume":"9","author":"AC van der Kuyl","year":"2012","unstructured":"van der Kuyl, A. C. HIV infection and HERV expression: a review. Retrovirology 9, 6 (2012).","journal-title":"Retrovirology"},{"key":"177_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/rmv.622","volume":"19","author":"E Balada","year":"2009","unstructured":"Balada, E., Ordi-Ros, J. & Vilardell-Tarr\u00e9s, M. Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity. Rev. Med. Virol. 19, 273\u2013286 (2009).","journal-title":"Rev. Med. Virol."},{"key":"177_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1099\/vir.0.79791-0","volume":"85","author":"J-M Yi","year":"2004","unstructured":"Yi, J.-M., Kim, H.-M. & Kim, H.-S. Expression of the human endogenous retrovirus HERV-W family in various human tissues and cancer cells. J. Gen. Virol. 85, 1203\u20131210 (2004).","journal-title":"J. Gen. Virol."},{"key":"177_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1593\/neo.07986","volume":"10","author":"M Golan","year":"2008","unstructured":"Golan, M. et al. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia 10, 521\u2013533 (2008).","journal-title":"Neoplasia"},{"key":"177_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.20892\/j.issn.2095-3941.2016.0080","volume":"13","author":"M Gonzalez-Cao","year":"2016","unstructured":"Gonzalez-Cao, M. et al. Human endogenous retroviruses and cancer. Cancer Biol. Med. 13, 483\u2013488 (2016).","journal-title":"Cancer Biol. Med."},{"key":"177_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41576-019-0165-8","volume":"20","author":"LM Payer","year":"2019","unstructured":"Payer, L. M. & Burns, K. H. Transposable elements in human genetic disease. Nat. Rev. Genet. 20, 760\u2013772 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"177_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.6004\/jnccn.2019.7287","volume":"17","author":"V Walter","year":"2019","unstructured":"Walter, V. et al. Decreasing use of chemotherapy in older patients with stage III colon cancer irrespective of comorbidities. JNCCN J. Natl Compr. Cancer Netw. 17, 1089\u20131099 (2019).","journal-title":"JNCCN J. Natl Compr. Cancer Netw."},{"key":"177_CR23","doi-asserted-by":"publisher","unstructured":"Minicozzi, P. et al. Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: a population-based European study. Eur. J. Surg. Oncol. https:\/\/doi.org\/10.1016\/J.EJSO.2020.02.023 (2020).","DOI":"10.1016\/J.EJSO.2020.02.023"},{"key":"177_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/1758834015587867","volume":"7","author":"S Upadhyay","year":"2015","unstructured":"Upadhyay, S., Dahal, S., Bhatt, V. R., Khanal, N. & Silberstein, P. T. Chemotherapy use in stage III colon cancer: a National Cancer Database analysis. Ther. Adv. Med. Oncol. 7, 244 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"177_CR25","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1172\/JCI121476","volume":"128","author":"CC Smith","year":"2019","unstructured":"Smith, C. C. et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J. Clin. Invest. 128, 4804\u20134820 (2019).","journal-title":"J. Clin. Invest."},{"key":"177_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41588-019-0373-3","volume":"51","author":"HS Jang","year":"2019","unstructured":"Jang, H. S. et al. Transposable elements drive widespread expression of oncogenes in human cancers. Nat. Genet. 51, 611\u2013617 (2019).","journal-title":"Nat. Genet."},{"key":"177_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13035-2","volume":"10","author":"Y Kong","year":"2019","unstructured":"Kong, Y. et al. Transposable element expression in tumors is associated with immune infiltration and increased antigenicity. Nat. Commun. 10, 5228 (2019).","journal-title":"Nat. Commun."},{"key":"177_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/0008-5472.CAN-15-3139","volume":"76","author":"E Cherkasova","year":"2016","unstructured":"Cherkasova, E. et al. Detection of an immunogenic HERV-E envelope with selective expression in clear cell kidney cancer. Cancer Res. 76, 2177\u20132185 (2016).","journal-title":"Cancer Res."},{"key":"177_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1172\/JCI34409C1","volume":"118","author":"Y Takahashi","year":"2008","unstructured":"Takahashi, Y. et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J. Clin. Invest. 118, 1099\u20131109 (2008).","journal-title":"J. Clin. Invest."},{"key":"177_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fonc.2013.00243","volume":"3","author":"E Cherkasova","year":"2013","unstructured":"Cherkasova, E., Weisman, Q. & Childs, R. W. Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors. Front. Oncol. 3, 243 (2013).","journal-title":"Front. Oncol."},{"key":"177_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"177_CR32","doi-asserted-by":"publisher","first-page":"e26476","DOI":"10.7554\/eLife.26476","volume":"6","author":"J Racle","year":"2017","unstructured":"Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E. & Gfeller, D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 6, e26476 (2017).","journal-title":"Elife"},{"key":"177_CR33","doi-asserted-by":"publisher","unstructured":"Chowell, D. et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat. Med. 1\u20136. https:\/\/doi.org\/10.1038\/s41591-019-0639-4 (2019).","DOI":"10.1038\/s41591-019-0639-4"},{"key":"177_CR34","doi-asserted-by":"publisher","first-page":"40095","DOI":"10.18632\/oncotarget.5539","volume":"6","author":"P P\u00e9rot","year":"2015","unstructured":"P\u00e9rot, P. et al. Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget 6, 40095\u201340111 (2015).","journal-title":"Oncotarget"},{"key":"177_CR35","doi-asserted-by":"publisher","first-page":"e24071","DOI":"10.1200\/JCO.2018.36.15_suppl.e24071","volume":"36","author":"S del Bue","year":"2018","unstructured":"del Bue, S. et al. Hypomethylation and presence of human endogenous retroviruses -h and -k in the extracellular microvescicles of colon cancer patients. J. Clin. Oncol. 36, e24071 (2018).","journal-title":"J. Clin. Oncol."},{"key":"177_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133\u2013150 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"177_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/1078-0432.CCR-18-1984","volume":"25","author":"HH Yoon","year":"2019","unstructured":"Yoon, H. H. et al. Intertumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch-repair\u2013deficient colon cancers: implications for prognosis. Clin. Cancer Res. 25, 125\u2013133 (2019).","journal-title":"Clin. Cancer Res."},{"key":"177_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16747-x","volume":"7","author":"PW Eide","year":"2017","unstructured":"Eide, P. W., Bruun, J., Lothe, R. A. & Sveen, A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci. Rep. 7, 16618 (2017).","journal-title":"Sci. Rep."},{"key":"177_CR39","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.6004\/jnccn.2019.0044","volume":"17","author":"S Gupta","year":"2019","unstructured":"Gupta, S. et al. NCCN guidelines insights: genetic\/familial high-risk assessment: colorectal, version 2.2019. J. Natl Compr. Cancer Netw. 17, 1032\u20131041 (2019).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"177_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1078-0432.CCR-11-1997","volume":"18","author":"NFCC de Miranda","year":"2012","unstructured":"de Miranda, N. F. C. C. et al. Infiltration of lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases. Clin. Cancer Res. 18, 1237\u20131245 (2012).","journal-title":"Clin. Cancer Res."},{"key":"177_CR41","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-15-2233","volume":"22","author":"MK McConechy","year":"2016","unstructured":"McConechy, M. K. et al. Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis. Clin. Cancer Res. 22, 2865\u20132873 (2016).","journal-title":"Clin. Cancer Res."},{"key":"177_CR42","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang, F. et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 5, 1504 (2019).","journal-title":"JAMA Oncol."},{"key":"177_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/labinvest.2015.131","volume":"96","author":"KM Hardiman","year":"2016","unstructured":"Hardiman, K. M. et al. Intra-tumor genetic heterogeneity in rectal cancer. Lab. Investig. 96, 4\u201315 (2016).","journal-title":"Lab. Investig."},{"key":"177_CR44","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/annonc\/mdz387","volume":"30","author":"S Stintzing","year":"2019","unstructured":"Stintzing, S. et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann. Oncol. 30, 1796\u20131803 (2019).","journal-title":"Ann. Oncol."},{"key":"177_CR45","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.18.02258","volume":"37","author":"H-J Lenz","year":"2019","unstructured":"Lenz, H.-J. et al. Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB\/SWOG 80405 (Alliance). J. Clin. Oncol. 37, 1876\u20131885 (2019).","journal-title":"J. Clin. Oncol."},{"key":"177_CR46","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465\u2013478 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"177_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2353\/jmoldx.2008.070082","volume":"10","author":"S Ogino","year":"2008","unstructured":"Ogino, S. & Goel, A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagnostics 10, 13\u201327 (2008).","journal-title":"J. Mol. Diagnostics"},{"key":"177_CR48","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1245\/s10434-018-6462-1","volume":"25","author":"MR Weiser","year":"2018","unstructured":"Weiser, M. R. AJCC 8th edition: colorectal cancer. Ann. Surg. Oncol. 25, 1454\u20131455 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"177_CR49","doi-asserted-by":"publisher","unstructured":"So, A. et al. Evaluation of whole exome sequencing for quantitative immune cell type deconvolution in tumor. In Society for Immunotherapy of Cancer P590. https:\/\/doi.org\/10.1186\/s40425-018-0422-y (2018).","DOI":"10.1186\/s40425-018-0422-y"},{"key":"177_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"177_CR51","doi-asserted-by":"crossref","unstructured":"Chou, D. et al. Abstract 3732: analytical performance of TruSight\u00ae Tumor 170 on small nucleotide variations and gene amplifications using DNA from formalin-fixed, paraffin-embedded (FFPE) solid tumor samples. In Clinical Research (Excluding Clinical Trials) Vol. 77, 3732\u20133732 (American Association for Cancer Research, 2017).","DOI":"10.1158\/1538-7445.AM2017-3732"},{"key":"177_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."},{"key":"177_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003665","volume":"10","author":"CA Miller","year":"2014","unstructured":"Miller, C. A. et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput. Biol. 10, e1003665 (2014).","journal-title":"PLoS Comput. Biol."}],"container-title":["npj Genomic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00177-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00177-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:47:55Z","timestamp":1670014075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41525-021-00177-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1038\/s41525-021-00177-w","relation":{},"ISSN":["2056-7944"],"issn-type":[{"value":"2056-7944","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G., M.S., S.K., R.V., N.K., J.G., A.S., T.P., S.Z., and L.L. are current employees and shareholders of Illumina Inc. A.W., C.G., and J.Y. were employees and shareholders of Illumina Inc. during part of this study. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}